Phase II study of gemcitabine + cisplatin in patients with unresectable advanced gallbladder cancer. Multicenter study

Phase II study of gemcitabine + cisplatin in patients with unresectable advanced gallbladder cancer. Multicenter study - Phase II study of gemcitabine + cisplatin in patients with unresectable advanced gallbladder cancer. Multicenter study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009257

Enrollment

Registered

2012-11-04

Start date

2011-11-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable advanced gallbladder cancer

Interventions

chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patients of the gallbladder cancer with unresectable local progression or remote metastasis by imaging diagnosis in Nagoya University digestive organ internal medicine and a Nagoya University-affiliated institution and agreed our study.

Exclusion criteria

Exclusion criteria: (1)interstitial pneumonia or pulmonary fibrosis(2)a case with uncontrolable diabetes,liver damage angina pectoris or acute myocardial infarction within three months(3)sever infection(4)brain metastasis with symptons(5)overlap cancer(6)sever edema,Ascites,pleural effusion(7) Case with possibility of pregnancy,during nursing(8)sever drug allergy(9)sever complications(10) In addition, the case judged to be inappropriate for the examination to carry out this study safely

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Time to progression,safety	—

Countries

Japan

Contacts

Public ContactHajime Sumi

Nagoya University Hospital Department of Endoscopy

sumi-h@med.nagoya-u.ac.jp052-744-2602

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026